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Abstract
Background: Innate neuroimmune dysfunction is a pathobiological feature of amyotrophic lateral sclerosis (ALS). However,
links, if any, between disease and adaptive immunity are poorly understood. Thus, the role of T cell immunity in disease was
investigated in human G93A superoxide dismutase 1 (SOD1) transgenic (Tg) mice and subsequently in ALS patients.
Methods and Findings: Quantitative and qualitative immune deficits in lymphoid cell and T cell function were seen in
G93A-SOD1 Tg mice. Spleens of Tg animals showed reductions in size, weight, lymphocyte numbers, and morphological
deficits at terminal stages of disease compared to their wild-type (Wt) littermates. Spleen sizes and weights of pre-
symptomatic Tg mice were unchanged, but deficits were readily seen in T cell proliferation coincident with increased
annexin-V associated apoptosis and necrosis of lymphocytes. These lymphoid deficits paralleled failure of Copolymer-1
(COP-1) immunization to affect longevity. In addition, among CD4
+ T cells in ALS patients, levels of CD45RA
+ (naı ¨ve) T cells
were diminished, while CD45RO
+ (memory) T cells were increased compared to age-matched caregivers. In attempts to
correct mutant SOD1 associated immune deficits, we reconstituted SOD1 Tg mice with unfractionated naı ¨ve lymphocytes or
anti-CD3 activated CD4
+CD25
+ T regulatory cells (Treg) or CD4
+CD25
2 T effector cells (Teff) from Wt donor mice. While naive
lymphocytes failed to enhance survival, both polyclonal-activated Treg and Teff subsets delayed loss of motor function and
extended survival; however, only Treg delayed neurological symptom onset, whereas Teff increased latency between
disease onset and entry into late stage.
Conclusions: A profound and progressive immunodeficiency is operative in G93A-SOD1 mice and is linked to T cell
dysfunction and the failure to elicit COP-1 neuroprotective immune responses. In preliminary studies T cell deficits were also
observed in human ALS. These findings, taken together, suggest caution in ascribing vaccination outcomes when these
animal models of human ALS are used for study. Nonetheless, the abilities to improve neurological function and life
expectancy in G93A-SOD1 Tg mice by reconstitution with activated T cells do provide opportunities for therapeutic
intervention.
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Introduction
Innate immune dysfunction is a pathogenic feature of
amyotrophic lateral sclerosis (ALS) [1,2]. Transgenic (Tg) mice
overexpressing mutated human G93A superoxide dismutase 1
(SOD1) [3] recapitulate ALS pathobiology including neuroin-
flammatory responses and motor neuron degeneration [4–7].
Microglial inflammatory responses contribute to progressive
neuronal loss in SOD1 mutant Tg mice and in human ALS [8–
12]. Functional ties between adaptive immunity and neurodegen-
erative disease are known for Parkinson’s disease [13,14],
Alzheimer’s disease (AD) [15–17], and multiple sclerosis (MS)
[18,19]. Moreover, neuroprotective responses by Copolymer-1
(COP-1) immunization were observed in animal models of these
and other neurodegenerative disorders [20–30]. However, links
between adaptive immunity and ALS remains obscure. Changes
in T cell numbers and adaptive immune molecules in postmortem
ALS and SOD1 Tg mouse nervous system tissues were reported
[6,31–36]. Interestingly, such COP-1 immunization strategies
yielded mixed results in G93A-SOD1 mice [37–39]. Taken
together, these findings suggest a progressive immune dysfunction
in G93A-SOD1 mice.
Mutant SOD1 may play a role in progression of ALS as
microglia recovered from G93A-SOD1 mice induce increased
motoneuron injury than microglia from over-expressing wild-type
(Wt) human SOD1 [8,40]. Human ALS immunocytes show that
both activated monocytes and T cell numbers are linked to disease
progression [41,42]. These data are consistent with a disease
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in ALS progression [31,40,41,43].
Based on these observations, we investigated T cell phenotype
and function in G93A-SOD1 Tg mice and in ALS patients. In
support of our own observations and those made by others [38,39]
COP-1 immunization provided clinical benefit to only female
G93A-SOD1 Tg mice. We observed profound T cell functional
deficits in pre-symptomatic male G93A-SOD1 Tg mice spleen as
well as acute lymphopenia in end stage animals. Transfer of naı ¨ve
lymphoid cells from Wt donor mice to SOD1 Tg recipient mice
failed to affect survival or overcome the observed lymphopenia. As
COP-1 is linked to neuroprotective T regulatory cells (Treg) and
the modulation of neuroinflammatory responses [23,28,44], we
next investigated whether CD4
+CD25
+ Treg or CD4
+CD25
2 T
effector cells (Teff) could affect neurological deficits and survival.
Importantly, for SOD1 Tg mice, polyclonal-activated Wt Treg or
Teff administered by adoptive transfer extended longevity and
attenuated motor deficits. Treg delayed clinical symptom onset,
while Teff increased latency from onset to late stage disease. These
results together with supportive data in human ALS suggest the
presence of aberrant T cell subsets in disease.
Methods
Animals
Mice from two SOD1 Tg mouse strains expressing the G93A
mutation, B6SJL-TgN(SOD1*G93A)1Gur (stock number, 002726;
hereafter designated B6SJL SOD1 Tg) and B6.Cg-Tg(SOD1*
G93A)1Gur/J (stock number, 004435; hereafter designated B6
SOD1 Tg) [4], and age- and sex-matched Wt littermates were
obtained from Jackson Laboratory (Bar Harbor, ME). B6SJL SOD1
Tg mice survive from 16–20 weeks, while B6 SOD1 Tg mice have a
delayed survival phenotype of 19–22 weeks. Mice were randomly
separated to control and treatment groups upon receipt. All animal
procedures met with National Institutes of Health guidelines and
wereapprovedbytheInstitutionalAnimalCareandUseCommittee
(IACUC) of the University of Nebraska Medical Center.
Human Subjects
Experimental procedures involving human subjects were
conducted in conformance with the policies and principles
contained in the Federal Policy for the Protection of Human
Subjects (U.S. Office of Science and Technology Policy) and in the
Declaration of Helsinki.
COP-1 Immunization
B6 SOD1 Tg mice (7 weeks old) were immunized with 75 mgo f
COP-1 in 0.1 ml PBS weekly (q1wk) or every 2 weeks (q2wk), or
treated with PBS alone. Subcutaneous injections were adminis-
tered in the flanks with a 50 ml bolus given to each side.
Spleen Morphology, Weight, Viable Cell Counts
Spleens from Wt and Tg mice were measured and weighed.
Single cell suspensions were prepared by pressing spleens through
60 mm sterile wire mesh screens in Hanks’ balanced salt solution
(HBSS, Mediatech Inc., Herndon, VA). Erythrocytes were lysed
with ammonium chloride potassium buffer and leukocytes washed
by centrifugation. Numbers of viable splenic leukocytes were
determined by trypan blue exclusion of hemocytometer counts.
Lymphocyte Proliferation
Splenocytes from individual animals were plated in 96-well
round-bottom plates at 1610
6 cell/ml in RPMI medium 1640
(Gibco, Carlsbad, CA) supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 25 mM HEPES, 1 mM sodium
pyruvate, 16 nonessential amino acids, 55 mM 2-mercaptoetha-
nol, 100 units/ml penicillin, and 100 mg/ml streptomycin
(complete RPMI 1640) (Mediatech Inc.). Quadruplicate replicates
were stimulated with anti-CD3 (1 mg/ml) (clone 145-2C11, BD
Pharmingen), goat anti-IgM (20 mg/ml) (Jackson Immuno Re-
search, West Grove, PA) or cultured in media alone at 37uCi n5 %
CO2 for 3 days. From Tg mice immunized with COP-1 (Sigma-
Aldrich, St. Louis, MO), spleen cells were cultured in the presence
of COP-1 (5 mg/ml), concanavalin A (Con A, 2 mg/ml, Sigma-
Aldrich), or media for 5 days. Cells were pulsed for the final 18 hrs
of incubation with 1 mCi [
3H] methylated thymidine ([
3H]-TdR)
(MP Biomedicals ICN, Solon, OH), harvested onto glass-fiber
filters, and counted by b-scintillation spectrometry (Top Count,
Packard Instrument Co., Meriden, CT). Levels of spleen cell
proliferation for each animal were normalized to levels of
proliferation obtained from cells cultured in media alone and
were reported as a stimulation index.
Immunohistochemical Assays
Fresh frozen spleens of Tg mice and Wt littermates were
embedded in OCT media (Sakura Fintek, Torrance, CA) and
sectioned at 10 mm using a cryostat (CM1900, Leica, Bannock-
burn, IL). Sections were collected on slides and fixed in ice-cold
acetone-methanol (1:1) for 30 min. Slides were washed in
phosphate-buffered saline (PBS) at room temperature (RT) and
quenched for endogenous peroxidase activity in 3% hydrogen
peroxide in methanol for 15 min. Nonspecific staining was blocked
with 5% normal rabbit serum (NRS) (Vector Laboratories,
Burlingame, CA) in PBS for 1 hr. For immunostaining, primary
antibodies (clone designations and dilutions) included anti-CD3
(clone 17A2, 1:100), anti-CD19 (clone 1D3, 1:100), anti-F4/80
(clone BM8, 1:500) and anti-Gr-1 (clone RB6-8C5, 1:100) (all
obtained from eBioscience, San Diego, CA). Sections were
incubated with primary antibody diluted in PBS/5% NRS for
90 min at RT, washed in PBS and incubated with polyclonal
rabbit anti-rat immunoglobulin (1:400) (Dako, Capinteria, CA) for
30 min followed by streptavidin-horseradish peroxidase solution
(ABC Elite vector kit, Vector Laboratories) for 30 min. Staining
was visualized by addition of hydrogen peroxide substrate and
diaminobenzidine chromogen (DAB substrate kit for peroxidase,
Vector Laboratories) solution. Sections were counterstained with
hematoxylin (Surgipath Medical Industries, Inc., Richmond, IL),
dehydrated, covered with mounting media (Cytoseal 60, Kalama-
zoo, MI) and mounted with a glass coverslip. Slides were examined
under a light microscope (Eclipse E800, Nikon, Inc., Melville, NY)
and representative images captured at 1006 magnification.
Follicle counts, area per follicle, and densities of CD3, CD19,
F4/80 and Gr-1 expression were evaluated from 4 fields/animal
by digital image analysis using Image-Pro Plus version 4 software
(Media Cybernetics, Silver Spring, MD).
Flow Cytometric (FCM) Analysis of Mouse and Human
Leukocytes
Single cell suspensions of spleens from Wt and Tg mice were
stained with fluorescein isothiocyanate (FITC)-conjugated (clone
designate) anti-CD19 (1D3), anti-CD4 (RM4-4), anti-CD62L (Mel-
14), and anti-Gr-1 (RB6-8C5); phycoerythrin (PE)-conjugated
(clone) anti-CD4 (GK1.5), anti-CD8b (53-5.8), and F4/80 (BM8,
eBioscience); and allophycocyanin (APC)-conjugated (clone) anti-
CD3 (145-2C11) and anti-CD44 (1M7). All antibodies except where
indicated were obtained from BD Pharmingen (San Diego, CA).
Peripheral blood from 10 ALS patients and their age-matched
caregivers were collected in ethylenediaminetetraacetic acid (EDTA)
T Cells and ALS Mouse Survival
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and processed upon arrival at the University Nebraska Medical
Center. Complete blood count (CBC) and differential analysis for
each donor and patient were determined from samples obtained
prior to shipping. For FCM analysis, 20 ml of appropriate
fluorochrome-conjugated antibodies were added to 100 ml of whole
blood and incubated in the dark for 30 min at RT. Erythrocytes
were lysed and leukocytes fixed with FACS Lysing solution (BD
Biosciences). Antibodies (clone) utilized in these studies included
FITC-conjugated anti-CD8a (RPA-T8), anti-CD16 (55661), anti-
CD45RA (HI1100), and anti-CD19 (H1B19); PE-conjugated anti-
CD14 (55715) and anti-CD4 (OKT4); and APC-conjugated anti-
CD3 (UCHT1), anti-HLA-DR (LN3), and anti-CD45R0 (UCHL1).
Stained mouse and human leukocytes were evaluated by FCM
analysis using a FACSCalibur flow cytometer interfaced with
CellQuest software (BD-Biosciences, Immunocytometry Systems).
Electronic bit maps were utilized to encompass and gate
lymphocyte and monocyte subsets during FCM analysis.
Measures of Lymphocyte Apoptosis and Necrosis
Spleen cells from 14 weeks old Wt and Tg mice were evaluated as
fresh isolates or were stimulated for 24 or 48 hrs as for lymphocyte
proliferation. Harvested spleen cells were stained with annexin-V-
FITC(ApoptosisDetectionkit,Calbiochem/EMDBiosciences,Inc.,
San Diego, CA), PE-anti-Thy-1 (clone 53-2.1) to detect T cells, and
APC anti-CD45R/B220 (clone RA3-6B2) to detect B cells
(eBioscience). Actinomycin D (7-ADD; BD Pharmingen) was used
as a viable exclusion indicator for membrane permeability to
distinguish apoptotic (annexin-V
+7-ADD
2) from necrotic cells
(annexin-V
+7-ADD
+), the latter having lost membrane integrity.
Isolation and Purification of CD4
+CD25
+ (Treg) and
CD4
+CD25
2 (Teff) Cells
Treg and Teff cells were isolated as previously described [44].
Lymph nodes (cervical, mandibular, axillary, brachial, inguinal
and mesenteric) and spleens were harvested from male Wt B6
mice (9 weeks old). After lysis of red blood cells, T cell populations
were enriched by negative selection on CD3
+ T cell columns
(R&D Systems, Minneapolis, MN). CD3
+ T cells were further
passed through CD4
+ T cell subset enrichment column (R&D
Systems) to obtain a highly pure CD4
+ T cell population in the
eluted fraction. The CD4
+ T cell fraction was incubated with PE-
labeled anti-CD25 antibody (BD Pharmingen) followed by anti-PE
microbeads (Miltenyi Biotec, Auburn, CA) and subjected to
magnetic separation (Auto MACS, Miltenyi Biotec). Nonadherent
cells were eluted from the magnetic column and were enriched for
CD4
+CD25
2 Teff cells, while adherent cells eluted from the
column were enriched as CD4
+CD25
+ Treg cells. Purity of
nonadherent and adherent cell fractions were determined by FCM
analysis (FACSCalibur flow cytometer, BD Biosciences) using
antibodies that recognize disparate epitopes to CD3, CD19, CD4,
CD8, CD25, and Foxp3 (eBioscience). Prior to activation, fresh
isolates of Tregs were .95% CD4
+CD25
+Foxp3
+ while Teff were
.95% CD4
+CD25
2Foxp3
2. To activate and expand enriched T
cell populations, purified cells were cultured for 4 days in 24-well
plates at 1610
6 cells per ml of complete RPMI 1640 with 0.5 mg/
ml anti-CD3 (145-2C11; BD Pharmingen) and 3610
6 irradiated
splenocytes (3,300 rads). CD4
+CD25
+ T cells required the
addition of 100 U/ml of mouse recombinant interleukin (IL)-2
(R&D Systems) [44]. Furthermore, CD4
+CD25
+ Tregs exhibited
increased expression of mRNA for Foxp3, TGF-b and IL-10,
whereas Teff showed increased expression of IFN-c mRNA. Tregs
also inhibited anti-CD3 induced mitogenesis in a dose-dependent
manner (data not shown).
Adoptive Cell Transfers
Freshly isolated lymphocytes obtained from spleens of naı ¨ve Wt
B6 donor mice and anti-CD3 activated Treg or Teff cells after 4
days of stimulation in vitro were harvested, washed, and
resuspended in HBSS. To B6 SOD1 Tg recipient mice, 50610
6
lymphocytes or 1610
6 Treg or Teff cells in 0.25 ml of HBSS or
PBS alone were administered intravenous every 6 weeks at 7, 13,
and 19 weeks of age.
Body Weight and Clinical Signs
The initial sign of the disease is a high frequency resting tremor
that progresses to gait impairment, asymmetrical or symmetrical
paralysis of the hind limbs, followed by complete paralysis at end
stage. Beginning at 7 weeks of age, all animals were assessed
weekly for body weight and for signs of motor deficit with the
following 4 point-scoring system: 4 points if normal (no sign of
motor dysfunction), 3 points if hind limb tremors were evident
when suspended by the tail, 2 points if gait abnormalities were
present, 1 point for dragging of at least one hind limb, and 0 point
for symmetrical paralysis [modified from [45]. Disease onset was
determined at the earliest presentation of symptoms (i.e. score=3).
Mice that reached a clinical score of 0 or lost 20% of maximum
body weight were deemed unable to survive, removed from the
study, immediately euthanized, and scored as a terminal event.
Paw Grip Endurance (PaGE) Test
Grip strength of hind limbs of mice were assessed each week as
previously described [45]. Each mouse was placed on the wire-lid
of a conventional housing cage and gently shaken to prompt the
mouse to hold on to the grid. The lid was turned upside down and
the duration determined until the mouse released both hind limbs.
Each mouse was given three attempts with a maximum duration of
90 sec and the longest latency was recorded.
Rotarod Performance
Mice were pre-conditioned for 3 days prior to testing then
monitored for rotarod performance once every week starting at 7
weeks of age [39]. In brief, mice were placed on a partitioned
rotating rod (Rotamex Rota-rod apparatus, Columbus Instru-
ments, Columbus, OH) and tested at a 5, 10, and 15 rpm for a
maximum of 90 sec at each speed with a minimum of 5 min rest
between attempts. The overall rotarod performance (ORP) was
calculated as the area under the curve using Prism (version 4,
Graphpad Software, San Diego, CA) from the plot of the time that
the animal remained on the rod as a function of the rotation speed
Statistical Analyses
All values are expressed as mean6SEM. Differences among
normally distributed means were evaluated by Student’s t test for
two group comparisons or one-way ANOVA followed by
Bonferroni or Fisher’s LSD post-hoc tests for pairwise comparisons
amongst multiple data sets exhibiting equal variances or by
Dunnett’s post-hoc tests for data exhibiting unequal variances
(Statistica v7, StatSoft, Tulsa, OK, and SPSS v13, SPSS, Inc.,
Chicago, IL). Cox’s F-test comparison was performed for
comparison between treatment groups for Kaplan-Meier analyses.
Results
COP-1 Immunization of B6 SOD1 Tg Mice
Our initial works investigated whether COP-1 immunization of
B6 SOD1 Tg mice affect disease progression. In these experiments
we immunized male and female B6 SOD1 Tg mice with 75 mg
T Cells and ALS Mouse Survival
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week (q2wk), or animals were treated every week with PBS as
excipient controls. Kaplan-Meier analysis indicated that weekly
COP-1 immunization had an affect on the lifespan of SOD1 Tg
mice compared to PBS controls (p=0.0413), however immuniza-
tion every other week did not increase survival (p=0.1673)
(Fig. 1A). For mice immunized weekly with COP-1, the mean age
of survival increased by 9.9% compared to PBS controls
(p=0.006), while COP-1 immunization every other week
increased the mean age of survival by 6.1%, however this did
not reach significance (data not shown). Log-normal analysis of
mortality probability at 10 day intervals showed that COP-1
immunization every week and every other week initially provided
protective benefits compared to PBS controls; however, by 160
days of age, the probability of mortality for mice immunized every
other week evolved to that afforded by PBS controls (Fig. 1B).
Kaplan-Meier analysis of treated mice stratified for gender
indicated that increased survival by weekly immunization was
associated with female mice (p=0.0434), but had no effect on
survival of male Tg mice (Fig. 1C). Similarly, compared to PBS
treated controls, immunization with COP-1 every week increased
the mean age of survival for female, but not male Tg mice, and
immunization every other week produced no difference in mean
age of survival for either male or female Tg mice (Fig. 1D). These
results posed the question as to whether adaptive immunity was
fully functional in pre-symptomatic SOD1 Tg mice.
Impaired T Cell Immune Responses in SOD1 Tg Mice
Based on the failure of the COP-1 immunization strategies to
increase longevity in male SOD1 Tg mice, and preliminary data
showing diminished spleen size and immune responses with age,
we tested whether T cell responses were functional. These studies
revealed that T cell immune function elicited in B6 SOD1 Tg
male mice was significantly impaired by 19 weeks of age. Spleen
cells from 4 and 8 week-immune SOD1 Tg mice, stimulated in vitro
with COP-1 exhibited increased stimulation indices compared to
those cultured in media alone (dashed line), whereas cells from
PBS treated mice were unable to respond to COP-1 (Fig. 1E)
indicating that immunization strategies elicited functional COP-1
responsive T cells in early stage of the disease. However, after 12
weeks of weekly or bi-weekly immunizations, stimulation indices of
COP-1 stimulated spleen cells diminished to levels statistically
indiscernible from those of cells cultured in media alone indicating
that the T cell immune responses in those mice had waned. In
concomitant assays to test the overall functionality of all T cell
populations, we stimulated spleen cell cultures with Con A, a T
cell mitogen. Stimulation indices of Con A induced T cells from
B6 SOD1 Tg mice in all treatment groups after 4 and 8 weeks (at
11 and 15 weeks of age) were significantly above those of media
control cells (dashed line) (Fig. 1F), demonstrating the presence of
functional T cells in those mice. However in Tg mice at 19 weeks
of age, after 12 weeks of treatment, stimulation indices of Con A
stimulated T cells were indistinguishable from those cultured in
media alone. Regression analysis of stimulation indices of Con A
stimulated T cells from PBS controls indicated a progressively
diminished proliferative capacity of T cells that was strongly
associated with increasing age of B6 SOD1 Tg mice (r
2=0.6308,
p=0.002). Taken together these results suggest a global dysreg-
ulation of T cell function with age in SOD1 Tg mice.
Spleen Size, Weight and Cell Counts in SOD1 Tg Mice
Based on marginal protection achieved by COP-1 immuniza-
tion and progressively diminished T cell function with age, we next
investigated the adaptive immune system in disease whereby
spleens from B6SJL G93A-SOD1 Tg mice were compared at early
symptomatic stage (14 weeks of age) and end stage (20–22 weeks of
age) with those of age and sex-matched Wt littermate controls. All
Tg mice at 14 weeks of age exhibited hind limb tremors.
Morphologically, spleens from 14 weeks old B6SJL Tg mice were
identicalto those ofWtcontrols(Fig. 2A,leftpanel),whereas,spleens
from end stage mice showed marked reduction in size compared to
controls (Fig. 2A, right panel). Similarly, no differences in spleen
weights from pre-symptomatic and symptomatic B6SJL mice
compared to Wt were discerned, whereas at end stage, spleen
weights were diminished by 45% in B6SJL Tg mice (19 weeks old)
and by59% inB6 Tg mice (22 weeks old) (Fig. 2B). Nodifferences in
grossmorphologyorweightsfornon-lymphoidkidneysorliverswere
discernible between Tg and Wt mice at any age (data not shown).
For end stage B6 Tg mice, total viable spleen cell numbers were
diminishedby70%comparedtoWtcontrols,whereasno differences
in spleen cell numbers were observed between Tg and Wt mice in
early symptomatic stage (Fig. 2C).
Immune Tissue Analyses of SOD1 Tg Mice
To assess splenic architecture in end stage mice, we assessed
expression of CD3, CD19, F4/80, and Gr-1 in fresh frozen
sections from end stage B6 Tg mice (22 weeks old), B6SJL Tg mice
(19 weeks old), and age-matched Wt controls. Splenic architecture
in end stage B6 Tg and B6SJL Tg mice revealed remarkable
alterations in follicle number, size, and expression of hematopoi-
etic lineage markers compared to Wt B6 littermates. Splenic
follicular architecture appeared diminished with a greater number
of follicles in each field for B6 SOD1 Tg (Fig. 3B, 3E, 3H, and 3K)
and B6SJL SOD1 Tg (Fig. 3C, 3F, 3I, and 3L) mice compared to
Wt controls (Fig. 3A, 3D, 3G, and 3J). The density of CD3
+ T cells
in the spleen appeared unaltered in B6 Tg (Fig. 3B) or B6SJL Tg
(Fig. 3C) mice compared to Wt mice (Fig. 3A), while expression of
F/480 (Fig. 3D, 3E, and 3F) and Gr-1 (Fig. 3G, 3H, and 3I) in the
perifollicular area of spleen appeared increased in SOD1 Tg mice
and the density of CD19 expression by B cells within the follicles of
SOD1 Tg mice (Fig. 3K and 3L) appeared diminished compared
to Wt controls (Fig. 3J) .
These observations were validated by digital image analysis in B6
Wt and B6 SOD1 Tg mice. In Tg mice, splenic follicular area was
diminished by 67% (Fig. 4A) and numbers of follicles/mm
2 were
increasedby41%(Fig.4B)comparedtoWtcontrols.Nodifferencein
the densities of splenic CD3 expression could be ascertained between
Tg and Wt control mice (Fig. 4C). In the splenic perifollicular area of
Tg mice compared to Wt controls, the mean density of F4/80 was
increased by 47% (Fig. 4D), density of Gr-1 expressing cells was
increased by 165%(Fig.4E),while the intrafollicular densityof CD19
expression was diminished by 88% (Fig. 4F).
Impaired Lymphocyte Proliferation and Necrosis in
Spleens of SOD1 Tg Mice
BasedondiminishedTcellresponsesandobservationsofprofound
lymphopenia in G93A-SOD1 Tg mice at end stage, we assessed
splenic lymphocyte phenotype and function in early symptomatic (14
weeks old) B6SJL SOD1 Tg mice to detect early immune cell
aberrations in spleen. Flow cytometric analysis of CD62L and CD44
expression on CD4
+ gated splenic lymphocytes (Fig. 5A) demon-
strated a diminished percentage of CD4
+CD44
hiCD62L
lo memory T
cells and an increased percentage of CD4
+CD44
loCD62L
hi naı ¨ve T
cells compared to Wt mice which resulted in an increased ratio of
naı ¨ve/memory CD4
+ T cells in Tg mice compared to Wt controls
(Fig. 5B). To assess lymphocytic demise, we evaluated apoptotic
(annexin-V
+7-ADD
2) and necrotic (annexin-V
+7-ADD
+)l y m p h o -
cytesamongviableT cells(Thy-1
+) and B cells(CD45R/B220
+)fr o m
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PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2740Figure 1. Effect of COP-1 immunization in B6 SOD1 mice. Mice were treated with PBS (closed circles and black bars), COP-1 weekly (q1wk)
(open boxes and gray bars), or COP-1 every 2 weeks (q2wk) (open triangles and white bars). (A) Kaplan-Meier analysis of the proportion of surviving
SOD1 Tg mice as a function of age. Cox’s F-test comparison showed groups treated with PBS vs COP-1 q1wk (p=0.0413) or COP-1 q2wk (p=0.1151),
and COP-1 q1wk vs COP-1 q2wk (p=0.1673). (B) Log-normal analysis of mortality probability at 10 day intervals for mice treated with PBS, COP-1
q1wk, COP-1 q2wk. (C) Kaplan-Meier plot of the proportion of surviving female SOD1 Tg mice (left panel) or male SOD1 Tg mice (right panel) as a
function of age showing the gender effect. Cox’s F-test comparison showed female mice groups treated with PBS vs COP-1 q1wk (p=0.0434) or COP-
1 q2wk (p=0.2449), and COP-1 q1wk vs COP-1 q2wk (p=0.0846) and male mice groups treated with PBS vs COP-1 q1wk (p=0.4240) or COP-1 q2wk
(p=0.1615), and COP-1 q1wk vs COP-1 q2wk (p=0.1430). (D) Mean age of survival6SEM for 7–10 female or 5–6 male SOD1 Tg mice/group treated
T Cells and ALS Mouse Survival
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Tg mice and Wt controls. Flow cytometric analysis revealed that Tg
mice had a greater than 2-fold increase in the percentage of annexin-
V
+7-ADD
+ necrotic splenic T cells and a 30% increase in the
percentage of annexin-V
+7-ADD
2 apoptotic T cells compared to Wt
littermates (Fig. 5C). Similarly, percentages of necrotic (41%) and
apoptotic (38%) B cells were increased in Tg mice compared to
control mice.
To assess lymphoid cell function of early symptomatic B6SJL
SOD1 Tg mice at 14 weeks of age, we stimulated T cells with anti-
CD3 and B cells with anti-IgM and evaluated their proliferative
capacity of each lineage. T cell proliferation in B6SJL Tg mice was
significantly diminished compared to Wt littermates; however no
diminution of B cell function could be ascertained (Fig. 5D). The
diminished T cell proliferative responses thus confirmed our
previous findings (Fig. 1F). We also assessed whether lymphoid
cells from Tg and Wt mice were differentially susceptible to
activation-induced cell death at either 24 or 48 hrs post-activation,
however no differences in induction of apoptotic or necrotic T or
B cells at any time point after activation were observed (data not
shown).
with PBS, COP-1 q1wk, or COP-1 q2wk.
aP,0.05 compared to PBS treated mice with Bonferroni post-hoc tests. Spleen cells from B6 Tg mice treated
with PBS, COP-1 q1wk, or COP-1 q2wk were stimulated with (E) Cop-1 (5 mg/ml), (F) Con A (2 mg/ml) or cultured in media alone. Cells were pulsed
with [
3H]-TdR for the final 18 hrs of culture, harvested onto glass fiber filters and counted by b-scintillation spectrometry. Counts were normalized as
a ratio of those obtained from culture in media alone to generate a stimulation index for spleen cell proliferation from each animal. A stimulation
index of 1 is defined by spleen cells cultured in media alone (dashed line). Means of stimulation indices (6SEM) were determined from 4–5 mice/
group for (E) antigen-specific proliferation elicited by Cop-1 and (F) polyclonal T cell proliferation induced by the T cell mitogen, Con A.
aP,0.05,
above media control (stimulation index=1, dashed line); and
bP,0.05 compared to weeks 4 or 8 within each treatment group.
doi:10.1371/journal.pone.0002740.g001
Figure 2. Spleen changes in G93A-SOD1 Tg mice. (A) Morphology
and size of spleens from B6SJL SOD1 Tg mice and Wt littermates at 14
weeks of age (left panel) and 20 weeks of age (right panel).(B) Mean spleen
weightswerecomparedbetween B6SJL Wt littermatesandB6SJLSOD1 Tg
mice at 7, 16 and 19 weeks age and between B6 Wt and B6 SOD1 Tg mice
at 22 weeks age (n=5–9 mice/group). (C) Total spleen cell numbers were
compared between Wt littermates and B6SJL SOD1 Tg mice at 14 and 22
w e e k so fa g e .V a l u e sa r em e a n s 6SEM for 3–9 mice per group.
doi:10.1371/journal.pone.0002740.g002
Figure 3. Altered spleen architecture from end stage G93A-
SOD1 Tg mice. Representative photomicrographs of immunohisto-
chemistry are shown for expression of CD3, F4/80, Gr-1, CD19 of fresh
frozen spleen sections from end stage SOD1 Tg mice and age-matched
Wt controls. Photomicrographs in the left panels are from B6 Wt mice,
while middle and right panels show sections from B6 SOD1 Tg and
B6SJL SOD1 Tg mice, respectively. Sections are stained by immunoper-
oxidase (brown) for expression of (A, B, C) CD3 by T cells; (D, E, F) F4/80
by perifollicular macrophages; (G, H, I) Gr-1 immunoreactivity on
myeloid cells; and (J, K, L) CD19
+ on B cells. Sections are counterstained
with hematoxylin (blue).
doi:10.1371/journal.pone.0002740.g003
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Naı ¨ve Lymphoid Cells, or Activated Treg or Teff Subsets
Based on the above findings in SOD1 Tg mice demonstrating a
lack of protective response by COP-1 immunization in male mice,
diminished T cell functional capacity in early symptomatic and
late stage mice, and end stage lymphopenia, we tested a strategy to
rectify the lymphoid dysregulation and extend survival by adoptive
transfer of B6 Wt naı ¨ve lymphoid cells to recipient B6 SOD1 Tg
mice. B6 SOD1 Tg mice treated with 50610
6 naive spleen cells at
7, 13, and 19 weeks of age yielded no significant differences in the
cumulative proportion of survival (Fig. 6A, p=0.2035) or mean
age of survival (Fig. 6B, p=0.315) compared to PBS-treated mice.
However, mean clinical scores analyzed by factorial ANOVA
revealed significant improvement of reconstituted mice compared
to PBS-treated controls (Fig. 6C, p=0.000001). Additionally,
Kaplan-Meier analysis showed immune reconstituted (RCS) Tg
mice exhibited delayed symptom onset (clinical score=3) (Fig. 6D,
p=0.0012) as well as delayed entry into late stage (clinical
score=1) (Fig. 6E, p=0.0191). However, after onset of symptoms,
survival of reconstituted Tg mice trended to be diminished
compared to the PBS controls as determined by Kaplan-Meier
analysis (Fig. 6F, p=0.2021) and by mean latency after onset to
death for PBS-treated (64.562.6) and RCS (52.064.3) mice
(p=0.0167) (data not shown).
No significant differences in body weight were discerned between
RCS- and PBS-treated groups as a function of age by factorial
ANOVA (Fig. S1A, p=0.5824). Additionally,no differences inPBS-
treated or RCS groups were found in the cumulative proportion
Figure 4. Comparison of spleen architecture between Wt and SOD1 B6 Tg mice (22 weeks old). (A) Mean area/follicle and (B) mean
numbers of follicles/mm
2 were determined for B6 Wt and B6 SOD1 Tg mice from digital images taken at 1006 magnification (4 random fields/
mouse). Densities of (C) CD3
+ T cells, (D) F4/80
+ macrophages, (E) Gr-1
+ cells, and (F) CD19
+ B cells from concomitantly stained sections were
determined by digital image analysis from 1006magnifications using Image-Pro Plus software. Values are means6SEM for 3–6 mice per group.
doi:10.1371/journal.pone.0002740.g004
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10% loss of maximum body weight (data not shown). Although an
early effect in hind grip strength was observed between 10–13 weeks
of age as determined by PaGE, no effects were discernible thereafter
(Fig. S1B). Factorial ANOVA indicated no differences in motor
function as determined by ORP in PBS-treated or RCS groups over
their lifetime (Fig. S1C, p=0.8862).
Based on our previous results which demonstrated that
regulatory T cells were neuroprotective in a mouse model of
Parkinson’s disease [23,28,44], we evaluated whether activated T
cell subsets also provide analogous protection in SOD1 Tg mice.
Adoptive transfer of 1610
6 enriched polyclonal-activated Wt Treg
(CD4
+CD25
+) or Teff (CD4
+CD25
2) to B6 SOD1 Tg mice at 7,
13, and 19 weeks of age led to significant increases in longevity as
determined by Kaplan-Meier analysis (Fig. 7A) and mean age of
survival (Fig. 8A) compared to PBS-treated controls. Factorial
ANOVA of treatment and age showed that by 11–12 weeks of age,
clinical scores were increased by reconstitution of B6 Tg recipients
with activated Wt Treg or Teff compared to PBS controls (Fig. 7B,
p=0.00004). Moreover, entry into late stage disease (clinical
score=1) was delayed by reconstitution with Treg or Teff as
determined by Kaplan-Meier analysis (Fig. 7C) and mean age of
entry into late stage (Fig. 8B). Of interest, transfer of activated Wt
Treg, but not Teff to B6 Tg recipient mice delayed disease onset as
evaluated by clinical signs (clinical score=3) and as determined by
Kaplan-Meier analysis (Fig. 7D, p=0.002) and mean age of disease
onset (Fig. 8C, p,0.0003). On the other hand, transfer of activated
Wt Teff, but not Treg to B6 Tg recipients, increased the latency
from onset (clinical score=3) to entry into late stage (clinical
score=1) as determined by Kaplan-Meier analysis (Fig. 7E,
p=0.0098). Adoptive transfer of Treg or Teff affected weight gain
and loss as determined by factorial ANOVA for effects of treatment
as a function of age (Fig. S2A, p=0.0356). Transfer of activated
Teff, but not Treg delayed the age at which recipients lost $10% of
maximum body weight compared to PBS treatment as determined
by Kaplan-Meier analysis of proportion (Fig. 7F, p=0.003) and
mean age (Fig. 8D) of mice reaching $10% weight loss.
Adoptive transfer of either Treg or Teff to B6 SOD1 Tg mice
also improved motor function compared to PBS treated controls as
determined by factorial ANOVA for effect of treatment with age
on ORP (Fig. S2B, p=3.3610
28) and PaGE (Fig. S2C,
p=6.7610
211). Activated Wt Treg or Teff delayed loss of rotarod
performance as determined by Kaplan-Meier analysis of the
proportion (Fig. 9A) and mean age (Fig. 9B) of mice at which
$75% of ORP was reduced. Also transfer of activated Treg or
Teff delayed the initial loss of ORP compared to PBS controls as
determined by the cumulative percentage (Fig. 9C) and the mean
age (Fig. 9D) of mice that reach $25% loss of ORP. We also
assessed hind limb strength by PaGE. Compared to PBS controls,
adoptive transfer of activated Treg or Teff delayed the loss of hind
limb strength as determined by Kaplan-Meier analysis of the
cumulative percentage (Fig. 9E) and increased mean age (Fig. 9F)
of SOD1 Tg mice exhibiting $75% reduction of PaGE. In
addition, transfer of activated Wt Treg or Teff to Tg mice delayed
early loss of hind limb grip strength compared to controls as
Figure 5. Lymphocyte phenotype and function in G93A-SOD1
Tg mice. The phenotype and function of splenic lymphocytes from
B6SJL SOD1 Tg and Wt littermates were assessed by flow cytometric
analysis (FCM) and proliferation assays. (A) Representative dot plot for
FCM analysis of CD4
+ gated naı ¨ve (CD44
loCD62L
hi) and memory
(CD44
hiCD62L
lo) T cells from Wt (left) and SOD1 Tg (right) mice at 14
weeks of age. (B) Mean percentages (6SEM) of CD4
+ naı ¨ve and memory
T cells (left panel) and ratios of naı ¨ve/memory CD4
+ T cells (right panel)
were determined for 5 Wt and 5 B6SJL SOD1 Tg mice. (C) Percentages
of annexin-V
+7ADD
+ (necrotic) and annexin-V
+7ADD
2 (apoptotic) Thy-
1
+ T cells or CD45RB220
+ B cells amongst splenic lymphocytes were
assessed in Wt and B6SJL SOD1 Tg mice at 14 weeks of age. (D)
Lymphoproliferative responses of Wt littermates and B6SJL SOD1 Tg
mice at 14 weeks of age were evaluated after in vitro stimulation for 3
days with anti-CD3 (1 mg/ml), anti-IgM (20 mg/ml), or media alone.
Stimulation indices for [
3H]-TdR uptake by splenocytes from each
animal were determined from quadruplicate cultures and values
represent the mean6SEM for 5 mice per group.
doi:10.1371/journal.pone.0002740.g005
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age (Fig. 9G) and mean age (Fig. 9H) of mice that exhibit $25%
reduction of PaGE. Of interest, after one round of Treg and Teff
adoptive transfer at 49 days of age, Teff appear less efficient than
Treg to attenuate early grip loss in Tg mice, however after a
second round (at 91 days of age), the capacities to attenuate loss of
grip strength by Teff and Treg were comparable (Fig. 9G).
Preliminary Studies of Altered Adaptive Immunity in ALS
Patients
To assess immune alterations in ALS patients, we characterized
peripheral blood mononuclear cells (PBMC) from 10 ALS patients
and 10 age-matched caregivers. Peripheral blood counts indicated a
small, though insignificant increase in the number of leukocytes in
patients compared to caregivers. ALS patients exhibited an increase
in the mean percentage of polymorphonuclear neutrophils (PMNs)
(8.060.07610
9/L compared with 6.660.06610
9/L, p=0.022),
with slightly reduced levels of lymphocytes (20.7%62.4% compared
with 25.9%61.8, p=0.054), and no discernible differences in
monocyte levels (p=0.35). Flow cytometric analysis showed no
differences in levels of peripheral blood CD19
+ B cells or CD3
+ T
cells among patients and caregivers. However compared to
caregivers, ALS patients exhibited an 11.8% decrease in the
percentage of CD4
+CD8
2 T cells (p=0.032) and a 22.9% increase
in the frequency of CD4
2CD8
+ T cells (p=0.043) compared to age-
matched controls. Additionally, the CD45RA/CD45R0 (naı ¨ve/
memory) ratio among CD4
+ T cells of ALS patients (0.660.1) was
diminished by 45% compared to caregivers (1.160.2, p=0.028),
which was due to the diminution in levels of CD45RA
+ naı ¨ve T cell
among CD4
+ cells (37.2%62.5% compared with 47.6%65.1% for
caregivers, p=0.0435) and a concomitant increase in levels of
CD45R0
+ memory cells among CD4
+ T cells (62.1%62.6%
compared with 51.7%65.2% for caregivers, p=0.0465).
Discussion
Recent evidence in SOD1 Tg ALS mice suggest neuroimmune
dysregulation of microglia that play a role as key contributors of
disease progression and in orchestrating motor neuron death [5,8–
12,31]. Activation of glia cells and inflammatory processes
coincide with disease onset and progression of disease in SOD1
Tg mice [5,6,46–49]. Postmortem examinations of ALS neural
tissues reveal associations between innate immune and immune
Figure 6. Effect of total lymphocyte reconstitution on survival and clinical scores in B6 SOD1 Tg mice. B6 SOD1 mice (20 mice/group)
were treated with PBS (closed circles) or RCS (open circles) with 50610
6 naı ¨ve splenic lymphocytes. (A) Kaplan-Meier analysis of the proportion of
surviving SOD1 Tg mice as a function of age. P=0.2035 by Cox’s F-test for comparison of PBS and RCS groups. (B) Mean age of survival6SEM for 20
mice/group treated with PBS (black bar, 149.367.5 days) or reconstituted with naı ¨ve lymphocytes (RCS) (white bar, 151.567.5 days). Comparison of
treatment groups indicated p=0.315 by ANOVA. (C) Mean clinical scores (6SEM) of PBS- or RCS-treated SOD1 Tg mice as a function of age in weeks.
*P,0.05 compared to PBS treated group by factorial ANOVA and Fisher’s LSD post-hoc tests of treatment and age. (D) Kaplan-Meier analysis of age
and cumulative proportion of SOD1 Tg mice reaching onset of disease (clinical score=3). P=0.0012 by Cox’s F-test comparison of reconstituted mice
to those treated with PBS. (E) Kaplan-Meier analysis of age and proportion of SOD1 Tg reaching late disease stage (clinical score=1). P=0.0191 by
Cox’s F-test comparison of reconstituted mice to those treated with PBS. (F) Kaplan-Meier analysis of the cumulative proportion of SOD1 Tg mice
surviving after the time of disease onset (clinical score=3). P=0.2021 by Cox’s F test comparison of RCS and those mice treated with PBS.
doi:10.1371/journal.pone.0002740.g006
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PLoS ONE | www.plosone.org 9 July 2008 | Volume 3 | Issue 7 | e2740Figure 7. Effect of Treg and Teff on survival, clinical scores and weight loss in B6 SOD1 Tg mice. B6 G93A-SOD1 mice (14–15 mice/group)
were treated with PBS (closed circles), 1610
6 activated Treg (open boxes), or 1610
6 activated Teff (open triangles) at 7, 13, and 19 weeks of age. (A)
Kaplan-Meier analysis of the proportion of surviving SOD1 Tg mice as a function of age. Cox’s F-test comparison of groups treated with PBS vs Treg
(p=0.0054) or Teff (p=0.0002), and Treg vs Teff (p=0.2505). (B) Clinical scores of SOD1 Tg mice as a function of age in weeks. *P,0.05 compared to
PBS treated group at each time point by factorial ANOVA and Fisher’s LSD post-hoc tests. (C) Kaplan-Meier analysis for age and proportion of SOD1 Tg
reaching late disease stage (clinical score=1). Cox’s F-test comparison of groups treated with PBS vs Treg (p=0.006) or Teff (p=0.0003), and Treg vs
Teff (p=0.1883). (D) Kaplan-Meier analysis of age and cumulative proportion of SOD1 Tg mice reaching onset of disease (clinical score=3). Cox’s F-
test comparison of groups treated with PBS vs Treg (p=0.002) or Teff (p=0.4215), and Treg vs Teff (p=0.0014). (E) Kaplan-Meier analysis of the
cumulative proportion of SOD1 Tg mice and the time after disease onset (clinical score=3) to reach late stage (clinical score=1). Cox’s F test
comparison of groups treated with PBS vs Treg (p=0.2716) or Teff (p=0.0098), and Treg vs Teff (p=0.0055). (F) Kaplan-Meier analysis of the age and
the cumulative proportion of SOD1 Tg mice that exhibited a reduction of maximum body weight $10%. Cox’s F-test comparison of groups treated
with PBS vs Treg (p=0.2131) or Teff (p=0.003), and Treg vs Teff (p=0.0807).
doi:10.1371/journal.pone.0002740.g007
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borne macrophages, mast cells, increased number of dendritic
cells, elevated chemoattractant factors, major histocompatibility
complex (MHC) class I and II molecules, as well as infiltrating
CD4
+ and CD8
+ T lymphocytes surrounding degenerating
neurons and areas affected in ALS [6,31,32,34–36]. Systemic
immune aberrations in ALS patients include alterations in
macrophage activation profiles [41,42], elevated levels of comple-
ment proteins in sera [50], increased IL-13 producing T cells and
circulating neutrophils [51,52], lymphopenia with reduced
number of CD2
+ and CD8
+ T cells [53]. Studies of human
patients with neurodegenerative disorders including ALS, indicate
increased expression of molecules associated with adaptive
immunity, such as MHC class I, II and human leukocyte antigens
in brains, spinal cords, cerebrospinal fluid and sera [54,55].
Increased levels of monocyte chemoattractant protein (MCP)-1
and RANTES are detected in cerebrospinal fluid and sera from
ALS patients [56–59]. Several reports support that peripheral
Figure 8. Effect of Treg and Teff on mean age of survival, clinical scores and weight loss in B6 G93A-SOD1 Tg mice. B6 G93A-SOD1
mice were treated with PBS (black bars), 1610
6 activated Treg (gray bars), or 1610
6 activated Teff (white bars) at 7, 13, and 19 weeks of age. (A) Mean
age of survival6SEM for 14–15 SOD1 Tg mice/group treated with PBS (152.762.0 days), Treg (165.865.0 days), or Teff (170.163.4 days).
aP,0.04
compared to PBS-treated mice by ANOVA and Bonferroni post-hoc tests. (B) Mean age6SEM for SOD1 Tg mice reaching late stage (clinical score=1)
after treatment with PBS (136.963.1 days), Treg (153.565.8 days), or Teff (160.164.3 days).
aP,0.04 compared to PBS control group by ANOVA and
Bonferroni post-hoc tests. (C) Mean age6SEM for SOD1 Tg mice at disease onset (clinical score=3) after treatment with PBS (77.761.3 days), Treg
(89.862.7 days), or Teff (75.761.9 days).
aP=0.0003 compared to PBS control group by ANOVA and Bonferroni post-hoc tests. (D) Mean age6SEM for
SOD1 Tg mice that exhibit a reduction of maximum body weight $10% after treatment with PBS (147.262.5 days), Treg (152.863.7 days), or Teff
(159.764.0 days).
aP,0.04 compared to PBS control group by ANOVA and Bonferroni post-hoc tests.
doi:10.1371/journal.pone.0002740.g008
T Cells and ALS Mouse Survival
PLoS ONE | www.plosone.org 11 July 2008 | Volume 3 | Issue 7 | e2740Figure 9. Effect of Treg and Teff on motor function in B6 G93A-SOD1 Tg mice. B6 G93A-SOD1 mice (14–15 mice/group) were treated at 7,
13, and 19 weeks of age with PBS (closed circles and black bars), 1610
6 activated Treg (open boxes and gray bars), or 1610
6 activated Teff (open
triangles and white bars). (A) Kaplan-Meier analysis of the age and the cumulative proportion of SOD1 Tg mice that exhibited a $75% reduction of
overall rotarod performance (ORP). Cox’s F-test comparison of groups treated with PBS vs Treg (p=0.0377) or Teff (p=0.0084), and Tregs vs Teffs
(p=0.27). (B) Mean age6SEM for 14–15 SOD1 Tg mice/group at which mice exhibited a $75% reduction in ORP after treatment with PBS (142.162.8
days), Treg (154.065.6 days), or Teff (157.564.4 days).
aP,0.05 compared to PBS treated mice by ANOVA and Bonferroni post-hoc tests. (C) Kaplan-
Meier analysis of ages and cumulative proportion of SOD1 Tg mice that exhibited $25% reduction in ORP. Cox’s F-test comparison of groups treated
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[18,19]. Based on this evidence of concomitant induction of
adaptive immune responses and innate immune activation, the
possibility of common immune-activating pathways in ALS and
other neurodegenerative disorders justified the hypothesis for
adaptive immune dysfunction as a major mechanism in neuroim-
mune dysregulation in ALS. Indeed, we demonstrated that spleens
of SOD1 Tg mice at end stage display significant reductions in size
and weight and profound lymphopenia. Further, splenic architec-
ture and expression of lymphocyte antigens were markedly altered
in SOD1 Tg mice. Moreover, these immune aberrations were
preceded by several weeks prior to early disease with significant T
cell functional deficits, decreased lymphoproliferative responses in
vitro, altered ratios of naı ¨ve to memory CD4
+ T cells, and increased
percentage of necrotic and apoptotic T cells. Taken together, our
data in conjunction with a solitary report showing lymphopenia in
peripheral blood of end stage G93A-SOD1 mice [60] strongly
indicates the critical involvement of adaptive immune deficits in
mutant SOD1-associated pathology, while early presentation of
immune dysfunction prior to clinical symptoms and subsequent
demise, strongly argues for the possibility that immune dysfunction
and loss of adaptive immune cells reflect mechanisms other than
those associated with end stage disease. Moreover, these data
suggest a plausible explanation for the results observed in the
SOD1 Tg mouse in which several drugs previously shown to be
efficacious in survival studies, have failed to demonstrate efficacy
in human studies [61].
Induction of Treg that secrete anti-inflammatory cytokines and
neurotrophic factors [62–64], shifts from proinflammatory Th1 to
anti-inflammatory Th2 cells [65], and attenuation of microglial
responses[23,28]havebeenlinked tothe immunomodulatoryaction
of COP-1. Neuroprotective immunization strategies using COP-1
and COP-1 derivatives administered with or without complete
Freund’s adjuvant in low or high copy G93A-SOD1 Tg mice have
yielded disparate outcomes [37–39]. In the present study, COP-1
immunization elicited protection in terms of enhanced survival to
female G93A-SOD1 B6 Tg mice. As induction of Th2 cells is one
mechanism by which COP-1 mediates neuroprotection and benefits
with this strategy have been shown to be limited to female SOD1 Tg
mice as shown here and elsewhere [38], this restricted level of
neuroprotection was most probably due, at least in part, to
diminished T cell immune function in male SOD1 Tg mice as
demonstrated by the loss of antigen-induced responses in COP-1
immunized mice and, more so by the global dysfunction of T cell
immune responses to the polyclonal stimulators anti-CD3 and Con
A in pre-symptomatic and symptomatic stages of the disease. The
outcome of COP-1 immunization in male G93A-SOD1 B6 Tg mice
in our present study echoes the failure of TV-5010, a COP-1
derivative to enhance survival conducted in three independent
studies in G93A B6SJL SOD1, G93A B6 SOD1 and G37R SOD1
mutant mouse models [39].
Weinitiallyattempted tocorrectlymphoidhomeostasisandglobal
T cell dysfunction by reconstituting the peripheral immune
compartment. However reconstitution of B6 SOD1 Tg mice with
Wt naı ¨ve splenocytes at regular intervals only transiently delayed
clinical onset and entry to late stage, and yielded no significant effect
on survival. This indicated that repopulation of the immune
compartment, though capable of transient delay of early and late
stage disease, was not sufficient to extend survival in SOD1 Tg mice.
As regulatory T cells are known to suppress immune activation,
maintain immune homeostasis, attenuate microglia activation and
provide beneficial compensation in neurodegeneration
[21,23,28,37,44,66,67], we next employed a reconstitution strategy
with polyclonal-activated Wt Treg or Teff beginning at the pre-
symptomatic stage of SOD1 Tg mice to maintain immune
homeostasis and neurological function, and enhance longevity in
SOD1 Tg mice. Not only did activated Treg attenuate motor
deficits and enhance survival in Tg animals, but activated Teff were
equally as effective for these parameters. Interestingly, Treg
delayed the onset of symptoms, while Teff cells increased the
latency from symptom onset to entry into the terminal phase and
also delayed weight loss. Thus, these differential pathways toward a
shared protective outcome of disease progression suggest distinct
underlying mechanisms conferred by Treg and Teff in neuropro-
tection with the effects of Treg acting primarily on the afferent
response limb. This is congruent with reported activities of
CD4+CD25+ Treg and Teff; i.e., Treg typically act on afferent
or induction of immune responses, whereas Teff are efferent
effectors. Thus neuroprotective Treg and Teff most probably act
via several independent pathways. The implication of macrophages
and microglia in disease progression in ALS and SOD1 Tg mice
[1,8,9,68,69] and evidence of Treg-mediated regulation of
microglia function [21,44,70], suggest that Treg affect the
induction phase of those cells. Delayed disease onset in SOD1
Tg mice supports that suggestion. On the other hand, the delay of
entry to late stage disease after onset by activated Teff cells, suggests
that protective populations are acting to attenuate already activated
myeloid populations. These results taken together suggest a possible
role for polyclonal-activated regulatory T cells in ALS therapy.
Immune dysregulation affecting both adaptive and innate
immune systems have a consistent hallmark in ALS [6]. We
report for the first time that compared to caregivers, ALS patients
exhibited diminished CD45RA/CD45R0 (naı ¨ve/memory) ratios
within the CD4
+ T cell subset. Diminished levels of naı ¨ve
(CD45RA) T cells and increased levels of memory (CD45R0)
CD4
+ T cells were coincidently responsible for diminution of
naı ¨ve/memory ratios among ALS patients. Evidence of dysregu-
lation within the peripheral adaptive immune system of ALS
patients reveals many adaptive immune deficits. Peripheral blood
lymphocytes from ALS patients have been reported to exhibit
abnormalities in mitochondrial and calcium metabolism [71],
reduced levels of metabotropic glutamate receptor 2 mRNA [72],
altered expression of antioxidant proteins and responses to nitric
oxide [73,74], and reduced expression of dopamine transporter
[75]. More recent evidence that includes increased levels of
circulating monocytes and macrophages [41], IL-13 producing T
with PBS vs Treg (p=0.0054) or Teff (p=0.0020), and Treg vs Teff (p=0.20). (D) Mean age6SEM for 14–15 SOD1 Tg mice/group at which mice
exhibited $25% reduction in ORP after treatment with PBS (117.763.5 days), Treg (136.566.2 days), or Teff (143.766.1 days).
aP,0.0025 compared to
PBS treated mice by ANOVA and Bonferroni post-hoc tests. (E) Kaplan-Meier analysis for age and proportion of SOD1 Tg mice that exhibited $75%
reduction of maximum Paw Grip Endurance (PaGE) after treatment with PBS, Treg, or Teff. Cox’s F test comparison of groups treated with PBS vs Treg
(p=0.001) or Teff (p=0.0003), and Treg vs Teff (p=0.14). (F) Mean age6SEM for SOD1 Tg mice that exhibited $75% reduction of maximum PaGE
after treatment with PBS (94.565.6 days), Treg (131.164.2 days), or Teff (137.264.5 days).
aP,0.0001 compared to PBS control group by ANOVA and
Bonferroni post-hoc tests. (G) Kaplan-Meier analysis for age (days) and proportion of SOD1 Tg mice that exhibited $25% reduction of maximum PaGE
after treatment with PBS, Treg, or Teff. Cox’s F test comparison of groups treated with PBS vs Treg (p,0.0001) or Teff (p=0.0033), and Treg vs Teff
(p=0.42). (H) Mean age6SEM at which SOD1 Tg mice exhibited at least 25% reduction of maximum PaGE after treatment with PBS (68.563.6 days),
Treg (119.167.2 days), or Teff (108.7611.3 days).
aP,0.002 compared to PBS control group by ANOVA and Dunnett’s post-hoc tests.
doi:10.1371/journal.pone.0002740.g009
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activated peripheral immune system. Although in our patient
cohort acute lymphopenia was not evident, the level of lymphocyte
frequency trended lower in ALS patients. Nevertheless, evidence
linking immunodeficiency in ALS syndromes include the loss of
CD8
+ T cells in ALS patients [53] and the loss of CD4
+ T cells in
HIV-infected patients that displayed ALS-like syndromes [77,78].
Moreover, disease onset in Guamanian patients exhibiting ALS-
inclusive syndromes has been linked to immunodeficiency and loss
of T cell-mediated immunity including lymphopenia, diminished
frequency and total number of peripheral T cells, diminished
responses to skin-test antigens, and decreased T cell responses to
mitogens [79–81]. These findings are in agreement with loss of T
cell function and lymphopenia in SOD1 Tg mice. In contrast to 14
weeks old SOD1 Tg mice, which showed among CD4
+ T cells,
increased naı ¨ve and decreased memory T cells, ALS patients in
this study, exhibited a significant loss of naı ¨ve CD4+ T cells and
gain of memory CD4
+ T cells. The reason for the discrepancy
between humans and mice is not clear at this point, however
possible explanations include contrasting differences in the murine
model of familial ALS and sporadic human ALS, differences in
homeostatic mechanism of peripheral blood lymphocytes and
murine splenic T cells, or more likely, represents differences in T
cell replenishment in relatively younger mice with a functional
thymus compared to relatively aged patients in which thymic
function is diminished. Nevertheless, compared to normal age-
matched controls, our findings emphasize the peripheral immune
dysfunction in T cell phenotypes in ALS patients and in SOD1 Tg
mice, both T cell phenotype and function.
Here, we present compelling evidence for adaptive immune
deficits in ALS. Vaccination with COP-1 to induce regulatory T
cells in G93A-SOD1 ALS mice that are genetically encoded for
immune deficits, most probably underlies the failure of immune
strategies to induce T cells resulting in lack of neuroprotective
immune responses in SOD1 Tg mice. Reconstituting a dysfunc-
tional immune system with activated T cell subsets, but not naı ¨ve
lymphocytes afforded improved neurological function and extend-
ed survival in SOD1 Tg mice. Thus, evidence in SOD1 Tg mice
of progressive immunological deficits warrants caution in the
interpretation of studies utilizing immunopharmacologic interven-
tions in the SOD1 Tg model and in ALS patients.
Supporting Information
Figure S1 Adoptive transfer of Wt naı ¨ve lymphoid cells on weight
and motor function of B6 G93A-SOD1 Tg mice. B6 G93A-SOD1
Tg mice (14–15 mice/group) were treated with PBS (closed circles)
or 50610 6 Wt naı ¨ve spleen cells (open circles), i.v. (A) Mean body
weights of treated SOD1 Tg mice were normalized to percentage of
maximum weight (6SEM) and analyzed as a function of age in
weeks.Factorial ANOVA ofpercentmaximumbodyweightsdid not
discern an effect of treatment (p=0.1424) or of combined treatment
and age (p=0.5824). (B) Mean percentage of maximum paw grip
endurance (PaGE)6SEM of treated SOD1 Tg mice were analyzed
as a function of age in weeks. Factorial ANOVA did not discern a
significant overall effect of treatment (p=0.5840), but indicated a
combined effect of treatment and age between 10 and 13 weeks of
age (p=0.001). *P,0.05 compared to PBS-treated group at each
time point by Fisher’s LSD post-hoc tests. (C) Mean percentage of
overall rotarod performance (ORP)6SEM of treated SOD1 Tg
mice were analyzed as function of age in weeks. Factorial ANOVA
did not discern an effectof treatment (p=0.7551) or combined effect
of treatment and age (p=0.8662).
Found at: doi:10.1371/journal.pone.0002740.s001 (1.00 MB
DOC)
Figure S2 Adoptive transfer of anti-CD3 activated Wt Treg and
Teff on weight and motor function of B6 G93A-SOD1 Tg mice.
B6 G93A-SOD1 Tg mice (14–15 mice/group) were treated at 7,
13, and 19 weeks of age with PBS (closed circles), 16106 activated
Treg (open boxes), or 16106 activated Teff (open triangles). (A)
Mean body weights of treated SOD1 Tg mice were normalized to
percentage of maximum weight6SEM and analyzed as function
of age in weeks. Factorial ANOVA of percent maximum body
weights indicated a significant combined effect of treatment and
age (p=0.0356). *P,0.05 compared to PBS-treated group at each
time point by Fisher’s LSD post-hoc tests. (B) Mean percentage of
maximum overall rotarod performance (ORP)6SEM of treated
SOD1 Tg mice analyzed as function of age in weeks. Factorial
ANOVA indicated a significant combined effect of treatment and
age (p=3.361028). *P,0.05 compared to PBS-treated group at
each time point by Fisher’s LSD post-hoc tests. (C) Mean
percentage of maximum paw grip endurance (PaGE)6SEM of
treated SOD1 Tg mice were analyzed as function of age in weeks.
Factorial ANOVA indicated a significant combined effect of
treatment and age (p=6.7610211). *P,0.05 compared to PBS-
treated group at each time point by Fisher’s LSD post-hoc tests.
Found at: doi:10.1371/journal.pone.0002740.s002 (0.30 MB TIF)
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